XML 67 R56.htm IDEA: XBRL DOCUMENT v3.21.1
Commitments and Contingencies - Additional Information (Details) - USD ($)
1 Months Ended 3 Months Ended
Dec. 02, 2020
Sep. 30, 2020
Aug. 31, 2019
Mar. 31, 2021
Mar. 31, 2020
Oct. 31, 2016
Loss Contingencies [Line Items]            
Rent expense       $ 300,000 $ 600,000  
Research and development       $ 3,321,000 2,900,000  
Revenue Share Agreement | Oncimmune Limited            
Loss Contingencies [Line Items]            
Percentage of revenue share payment related to acquired diagnostic test recognized revenue for non-screening tests       8.00%    
Minimum annual volume percentage thereafter       5.00%    
Period of escalations of sales       through the first four years of sales    
Revenue share expenses       $ 200,000 74,400  
Bio-Rad License            
Loss Contingencies [Line Items]            
Percentage of royalty payments on net revenue     2.50%      
License expiry date     2024-08      
AVEO Oncology            
Loss Contingencies [Line Items]            
Remaining estimated obligation       300,000    
Research and development       $ 0 $ 600,000  
AVEO Oncology | NSCLC POC Trial            
Loss Contingencies [Line Items]            
Responsible percentage of development and regulatory costs           50.00%
Ficlatuzumab | AVEO Oncology            
Loss Contingencies [Line Items]            
Percentage of development and regulatory costs exercised using opt-out right   50.00%        
Percentage of royalty payments on net sales 10.00%          
Percentage of license income generated from licensing 25.00%          
BDX004 | Ficlatuzumab | AVEO Oncology | POC Clinical Trials            
Loss Contingencies [Line Items]            
Responsible percentage of development and regulatory costs           50.00%